REDWOOD
CITY, Calif., Aug. 23,
2023 /PRNewswire/ -- Nevro
Corp. (NYSE: NVRO), a global medical device company
delivering comprehensive, life-changing solutions for the treatment
of chronic pain, announced today that it is participating in the
following investor conferences:
- On September 7, 2023,
Kevin Thornal, Chief Executive
Officer and President, and Rod
MacLeod, Chief Financial Officer will present at the Wells
Fargo Healthcare Conference at 4:30 PM
ET at the Encore Boston Harbor Hotel in Boston, MA.
- On September 11, 2023,
Kevin Thornal, Chief Executive
Officer and President, and Rod
MacLeod, Chief Financial Officer will present at the Morgan
Stanley 21st Annual Global Healthcare Conference at
12:55 PM ET at the Sheraton New York
Times Square Hotel in New York,
NY.
A webcast of these events, as well as archived recordings, will
be available in the Investors section of Nevro's website
at www.nevro.com.
Internet Posting of Information
Nevro routinely posts
information that may be important to investors in the "Investor
Relations" section of its website at www.nevro.com. The
company encourages investors and potential investors to consult the
Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global
medical device company focused on delivering comprehensive,
life-changing solutions that continue to set the standard for
enduring patient outcomes in chronic pain treatment. The company
started with a simple mission to help more patients suffering from
debilitating pain and developed its proprietary 10 kHz Therapy™, an
evidence-based, non-pharmacologic innovation that has impacted the
lives of more than 100,000 patients globally. Nevro's comprehensive
HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS
system and support services for the treatment of chronic pain of
the trunk and limb, with and without surgery, and painful diabetic
neuropathy.
Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS
systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's
unique support services provide every patient with an HFX Coach™
throughout their pain relief journey and every physician with HFX
Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo,
RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are
trademarks or registered trademarks of Nevro Corp. Patents covering
Senza HFX iQ and other Nevro products are listed at
Nevro.com/patents.
To learn more about Nevro, connect with us
on LinkedIn, Twitter, Facebook and Instagram.
Investors and Media:
Greg
Chodaczek
347-620-7010
ir@nevro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-announces-participation-in-upcoming-investor-conferences-301907563.html
SOURCE Nevro Corp.